Skip to content

Study · Randomized controlled trial · n = 60 · 2020

4 results

Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.

Hygum K, Harsløf T, Jørgensen NR, Rungby J, Pedersen SB, Langdahl BL

Bone20 Dec 2019Cited by 64 (Europe PMC)

PMID31870634 (opens in a new tab)DOI10.1016/j.bone.2019.115197 (opens in a new tab)PepBankPUB-31870634
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, p-CTX rose in both groups, and the change did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, a bone breakdown marker rose in both groups, and liraglutide did not change it differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in p-CTX (bone resorption marker)
    Study

    n = 60

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    P-CTX increased in patients treated with liraglutide by 0.07 (0.03; 0.10) μg/L (p < 0.001) and in patients treated with placebo by 0.03 (0.00; 0.06) μg/L (p = 0.04), however, changes were not different between the groups (p = 0.16).
    2 context sentences
    Summary · context
    The primary endpoint was change in p-collagen I cross-linked C-terminal telopeptide (p-CTX).
    Summary · context
    Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, body weight decreased with liraglutide from baseline to week four and remained stable thereafter, while weight did not change with placebo.

    In plain wordsIn adults with type 2 diabetes, weight fell in the first weeks of liraglutide and then stayed stable, while it did not change with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Weight decreased in patients treated with liraglutide from baseline to week four (p < 0.001) and remained stable thereafter.
    2 context sentences
    Summary · context
    Weight and p-P1NP did not change in patients treated with placebo.
    Summary · context
    Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, P1NP decreased with liraglutide until week four, increased between weeks 4 and 13, and remained elevated thereafter; it did not change with placebo.

    In plain wordsIn adults with type 2 diabetes, a bone formation marker first fell and then rose with liraglutide, but did not change with placebo.

    Peptide
    Liraglutide
    Outcome
    MixedP1NP (bone formation marker)
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    P-procollagen type 1 N-terminal propeptide (P1NP) decreased in patients treated with liraglutide from baseline to week four (p < 0.01), increased between weeks 4 and 13 (p = 0.03), and remained elevated thereafter.
    2 context sentences
    Summary · context
    Weight and p-P1NP did not change in patients treated with placebo.
    Summary · context
    Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, hip bone mineral density fell with placebo but did not change with liraglutide, with a difference between groups.

    In plain wordsIn adults with type 2 diabetes, hip bone density stayed unchanged with liraglutide but fell with placebo.

    Peptide
    Liraglutide
    Outcome
    MixedHip bone mineral density
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Hip bone mineral density (BMD) decreased in placebo treated patients from baseline to end of study, whereas no changes were seen in patients treated with liraglutide (p = 0.01 difference between groups).
    1 context sentence
    Summary · context
    Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07094568

Tirzepatide vs Liraglutide in Bone

National and Kapodistrian University of Athensn = 7223 May 2025 to est. 30 Dec 2026

Obesity (Disorder)

Trial pageClinicalTrials.govUpdated 21 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.